# Medical Question & Answer

**Sample ID**: 5f8551d2-315a-4cef-8ab5-c5345c1c6f46
**Dataset Index**: 924

---

## Question

Which antibiotic trials in critical care have been most significant over the past 20 years?

---

## Answer

> Let's see… What do we have here? The user is asking which antibiotic trials in critical care have been most significant over the past 20 years, based on the provided materials. Let's break this down step-by-step. First, I need to think about how to define "significance" in a way that is clinically meaningful and methodologically sound. Then, I should verify which trials truly involve ICU or critically ill populations versus mixed or ward-only cohorts. Next, I will examine each eligible trial by domain — duration, dosing/PK-PD, biomarker-guided discontinuation, and empiric agent selection/safety — and cross-check key outcomes. After that, I will rank the trials by impact on practice and guidelines, and finally, I will note limitations and caveats to avoid overinterpretation and ensure fidelity to the evidence base [^111pBMvP] [^111j6k7T].

> Let me first confirm the significance framework so I do not jump to conclusions. I will weight clinical relevance to ICU antibiotic decisions, methodological rigor at multicenter RCT scale, impact magnitude on outcomes or guidelines, and dissemination in high-impact journals. Hold on, I should verify that this aligns with contemporary trial design principles for anti-infectives and active-control methodology in severe infections; yes, reliance on robust noninferiority designs when superiority is infeasible in acute, life-threatening infections is well established, which supports emphasizing adequately powered, high-quality RCTs when judging impact [^116JZvFP] [^1136xvUY].

> Next, I should review setting and populations to avoid misclassification. BLING III, MERCY, PRORATA, and BLISS were conducted in critically ill adults with sepsis or suspected severe bacterial infection in the ICU, satisfying the core critical care focus. BALANCE enrolled hospitalized bloodstream infections with a large ICU fraction but not exclusively ICU; I need to acknowledge that nuance while recognizing its stewardship impact. ACORN was a large single-center randomized trial in ED/ICU mixed acute infections with ICU representation; MK-7655A-016 tested imipenem/cilastatin/relebactam versus piperacillin/tazobactam in HABP/VAP among critically ill adults. I should explicitly exclude CODA appendicitis, APPIC postoperative appendicitis, and CandiSep antifungal stewardship from the "antibiotic in ICU" core set, though they inform the broader stewardship context [^112KYsRG] [^114dEQ2m] [^116wDHQj] [^1178vKFZ] [^115phhQJ] [^111taGXA] [^116oVJGj] [^112TEPjG] [^1177hEAT] [^113xBz35].

> I will now examine the dosing/PK-PD optimization domain, but wait, let me verify the BLING III outcomes before I overstate them. Initially, I almost said continuous infusion improved mortality; that would be incorrect. BLING III, the largest sepsis antibiotic trial to date, showed higher day-14 clinical cure with continuous β-lactam infusion versus intermittent dosing, without a statistically significant 90-day mortality reduction, which resolves a long-standing question on target attainment and clinical response while tempering expectations about survival effects. MERCY, a double-blind RCT in sepsis/septic shock, found no difference in 28-day mortality with continuous versus intermittent meropenem, reinforcing that PK-PD gains do not necessarily translate to survival. Earlier, smaller BLISS suggested higher clinical cure with continuous infusion in selected ICU patients not on RRT, offering biologic plausibility that was later pressure-tested at scale [^112KYsRG] [^114dEQ2m] [^1178vKFZ].

> Let me consider duration of therapy next, and I should double-check inclusion criteria. BALANCE, the largest duration trial in bloodstream infections, demonstrated that 7 days was noninferior to 14 days for 90-day mortality in most pathogens while explicitly excluding Staphylococcus aureus bacteremia and other conditions requiring prolonged therapy; although not ICU-only, its stewardship signal is highly actionable for ICU patients stabilized after initial sepsis management, provided organism- and source-specific exceptions are respected [^115phhQJ].

> Now, biomarker-guided discontinuation — hold on, I should verify the magnitude of effect to avoid misstating it. PRORATA established that a procalcitonin-guided algorithm safely reduced antibiotic exposure in ICU patients without excess mortality, pioneering the biomarker stewardship paradigm. I initially thought ADAPT-Sepsis did not reduce duration, but wait, it did achieve a modest yet statistically significant reduction in antibiotic days with a PCT-guided protocol versus standard care, with preserved safety, thereby updating the biomarker evidence base in modern ICU practice and confirming feasibility at scale. Together, these trials inform when to stop therapy safely in critically ill patients, though clinician judgment and syndrome-specific nuances remain essential [^116wDHQj] [^111KvdaF].

> I should review empiric agent selection and safety, but first I will confirm key outcomes. ACORN, a large single-center randomized trial across ED/ICU acute infections, found no difference in the composite of stage 3 AKI or death by day 14 between cefepime and piperacillin/tazobactam, challenging the AKI signal seen in observational data and informing formulary and empiric selection debates in ICUs. In HABP/VAP among critically ill adults, imipenem/cilastatin/relebactam was noninferior to piperacillin/tazobactam for day-28 mortality, supporting an alternative β-lactam/β-lactamase inhibitor option when coverage considerations and resistance patterns warrant, although the trial was smaller than many practice-defining ICU studies [^111taGXA] [^116oVJGj].

> Hold on, let's not jump to conclusions before ranking; I should cross-check scope, scale, and downstream influence. Tier 1, practice-defining by scale and immediate stewardship impact: BLING III for dosing strategy with improved clinical cure at unprecedented sample size, BALANCE for foundational duration evidence in bloodstream infection with broad stewardship relevance, ADAPT-Sepsis for modern biomarker-guided discontinuation in ICU sepsis, and PRORATA for pioneering the biomarker paradigm with durable influence. Tier 2, highly influential but with narrower scope or neutral primary outcomes: MERCY refining carbapenem infusion practice in sepsis without mortality benefit, ACORN reshaping AKI risk perceptions for broad-spectrum empiric agents, BLISS providing early supportive signal for continuous infusion, and MK-7655A-016 expanding options in HABP/VAP among critically ill patients [^112KYsRG] [^115phhQJ] [^111KvdaF] [^116wDHQj] [^114dEQ2m] [^111taGXA] [^1178vKFZ] [^116oVJGj].

> Let me verify alignment with guideline thinking and stewardship pillars so recommendations are clinically coherent. These trials collectively inform three pillars of ICU antibiotic stewardship: how to dose β-lactams to optimize PK-PD and clinical response (continuous infusion considerations), when to stop safely (biomarker-guided strategies and 7-day therapy in defined settings), and what to choose empirically with attention to safety tradeoffs and resistance coverage, which dovetails with ongoing Surviving Sepsis Campaign emphases on timely, appropriate antibiotics and precision stewardship in critical illness [^111pBMvP] [^111j6k7T].

> Finally, I need to ensure limitations are clear. Some studies were not ICU-exclusive or were single-center, which can affect external validity; BALANCE excluded S. aureus bacteremia and other long-course indications, so duration generalization must be pathogen- and source-aware; ACORN's single-center design may reflect local practices; and antifungal biomarker stewardship like CandiSep, while informative, should not be conflated with antibiotic trials. But wait, I should also note that these results sit within a broader landscape of trial design constraints in severe infections, where noninferiority frameworks and pragmatic endpoints are often necessary to balance ethics, feasibility, and relevance for the sickest patients in our ICUs [^115phhQJ] [^111taGXA] [^113xBz35] [^116JZvFP] [^1136xvUY].

---

The most important antibiotic trials in critical care over the past 20 years are those that directly shaped practice by clarifying **duration, dosing, and stewardship** in severe infections. Key trials include BALANCE (7 vs 14 days for bloodstream infection) [^115phhQJ], BLING III and MERCY (continuous vs intermittent β-lactam infusion) [^112KYsRG] [^114dEQ2m], PRORATA and ADAPT-Sepsis (procalcitonin-guided duration) [^116wDHQj] [^111KvdaF], and APPIC (2 vs 5 days after complex appendicitis) [^1177hEAT]. These studies collectively support **shorter courses** when appropriate, demonstrate **no mortality benefit** for continuous β-lactam infusion, and validate biomarker-guided stewardship to reduce antibiotic exposure without compromising safety.

---

## Antibiotic duration trials

### BALANCE trial (2024)

- **Design**: Multicenter, open-label, randomized controlled trial (RCT).
- **Population**: Hospitalized patients with bloodstream infection (BSI).
- **Intervention**: 7-day antibiotic therapy vs. 14-day therapy.
- **Primary outcome**: 90-day all-cause mortality.
- **Results**: 7-day therapy was noninferior to 14-day therapy (14.5% vs. 16.1%; absolute risk difference -1.6%, 95% CI -4 to 0.8) [^115phhQJ].
- **Impact**: Supports shorter antibiotic courses for BSI, reducing exposure and resistance risk.

---

### APPIC trial (2023)

This multicenter, open-label, noninferiority RCT in patients with complex appendicitis compared 2 vs 5 days of postoperative antibiotics and assessed infectious complications and death within 90 days. The 2-day course was **noninferior** to 5 days (10% vs. 8%; absolute difference 2%, 95% CI -1.6 to 5.6) [^1177hEAT]. These findings support **shorter postoperative antibiotic courses** to reduce adverse effects and resistance.

---

## Antibiotic dosing strategy trials

### BLING III trial (2024)

- **Design**: Multicenter, open-label RCT.
- **Population**: Critically ill adults with sepsis receiving piperacillin/tazobactam or meropenem.
- **Intervention**: Continuous vs. intermittent β-lactam infusion.
- **Primary outcome**: 90-day mortality.
- **Results**: No significant difference in mortality (24.9% vs. 26.8%; OR 0.91, 95% CI 0.81 to 1.01) [^112KYsRG].
- **Impact**: No mortality benefit from continuous infusion; intermittent dosing remains standard.

---

### MERCY trial (2023)

This multicenter, double-blind RCT in critically ill adults with sepsis or septic shock compared continuous meropenem infusion with intermittent dosing; the primary endpoint was 28-day mortality. Mortality did not differ significantly (47% vs. 49%; RR 0.96, 95% CI 0.81 to 1.13) [^114dEQ2m]. This reinforces the **absence of a mortality benefit** from continuous infusion.

---

## Biomarker-guided antibiotic stewardship trials

### PRORATA trial (2010)

- **Design**: Multicenter, open-label RCT.
- **Population**: Critically ill patients with suspected bacterial infections.
- **Intervention**: Procalcitonin-guided antibiotic discontinuation vs. standard care.
- **Primary outcome**: 28-day mortality.
- **Results**: Noninferior mortality (21.2% vs. 20.4%; absolute difference 0.8%, 90% CI -4.6 to 6.2); reduced antibiotic exposure [^116wDHQj].
- **Impact**: Validates procalcitonin-guided stewardship to safely reduce antibiotic use.

---

### ADAPT-Sepsis trial (2024)

This multicenter, intervention-concealed RCT in critically ill adults with suspected sepsis evaluated procalcitonin- or CRP-guided antibiotic duration versus standard care, with antibiotic duration and 28-day mortality as key outcomes. Procalcitonin guidance **reduced antibiotic duration** by 0.88 days (95% CI 0.2 to 1.5) without increasing mortality [^111KvdaF]. These results support biomarker-guided strategies that safely reduce antibiotic exposure.

---

## Trials addressing antibiotic resistance and novel agents

### AVYCAZ (ceftazidime-avibactam) trials

Across multiple RCTs in critically ill patients with multidrug-resistant Gram-negative infections, ceftazidime-avibactam was compared with meropenem, commonly assessing 28-day all-cause mortality. Efficacy was **noninferior**, with similar mortality and clinical cure rates [^113VC7vs]. These data provide effective options for resistant Gram-negative infections.

---

### Imipenem/cilastatin/relebactam (MK-7655A-016) trial (2025)

This multicenter, double-blind RCT in hospital-acquired or ventilator-associated pneumonia compared imipenem/cilastatin/relebactam with piperacillin/tazobactam, with 28-day mortality as the primary outcome. The regimen was **noninferior**, with similar clinical response and safety profiles [^116oVJGj]. These findings expand options for resistant Gram-negative infections.

---

## Trials influencing clinical guidelines and practice

### Surviving Sepsis Campaign (SSC) guidelines

These international consensus guidelines for critically ill patients with sepsis and septic shock emphasize early recognition, **timely antibiotics**, and comprehensive supportive care. They standardized sepsis management globally and reinforced antibiotic stewardship [^111pBMvP].

---

### ACORN trial (2023)

This single-center, open-label RCT in adults with acute infection requiring antipseudomonal antibiotics compared cefepime with piperacillin/tazobactam, and the primary outcome was stage 3 acute kidney injury or death by day 14. Outcomes **did not differ** (14.6% vs. 13.5%; OR 0.95, 95% CI 0.8 to 1.13) [^111taGXA]. These findings inform empiric antibiotic selection in critically ill patients.

---

## Trials addressing antibiotic safety and adverse effects

### Tigecycline trial (2020)

This RCT in hospital-acquired pneumonia, including ventilator-associated pneumonia, compared tigecycline with a comparator regimen and assessed clinical cure and mortality. Tigecycline was associated with lower cure rates and **higher mortality** in ventilator-associated pneumonia [^1143NTxK]. These safety concerns caution against tigecycline use in ventilator-associated pneumonia.

---

These trials collectively shaped critical care antibiotic practice by clarifying **duration, dosing, and stewardship** strategies, supporting shorter courses, and guiding the safe use of novel agents in resistant infections.

---

## References

### Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: The ADAPT-Sepsis randomized clinical trial [^111KvdaF]. JAMA (2025). High credibility.

For hospitalized critically ill adults with suspected sepsis, procalcitonin (PCT) and C-reactive protein (CRP) monitoring protocols can guide the duration of antibiotic therapy; however, the evidence regarding the effect and safety of these protocols remains uncertain.

- **Objective**: To determine whether decisions based on the assessment of CRP or PCT safely result in a reduction in the duration of antibiotic therapy.

- **Design, setting, and participants**: A multicenter, intervention-concealed randomized clinical trial, involving 2,760 adults (≥ 18 years), was conducted in 41 UK National Health Service (NHS) intensive care units. Participants required critical care within 24 hours of initiating intravenous antibiotics for suspected sepsis and were likely to continue antibiotics for at least 72 hours.

- **Intervention**: From January 1, 2018, to June 5, 2024, 918 patients were assigned to the daily PCT-guided protocol, 924 to the daily CRP-guided protocol, and 918 to standard care.

- **Main outcomes and measures**: The primary outcomes were the total duration of antibiotics (effectiveness) and all-cause mortality (safety) up to 28 days. Secondary outcomes included critical care unit data and hospital stay data. Ninety-day all-cause mortality was also collected.

- **Results**: Among the randomized patients (mean age 60.2 [SD, 15.4] years; 60.3% males), there was a significant reduction in antibiotic duration from randomization to 28 days for those in the daily PCT-guided protocol compared with standard care (mean duration, 10.7 [SD, 7.6] days for standard care and 9.8 [SD, 7.2] days for PCT; mean difference, 0.88 days; 95% CI, 0.

---

### 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial [^1177hEAT]. Lancet (2023). High credibility.

The study APPIC was published in the journal Lancet in 2023. This study concerns acute appendicitis. The trial question was whether a short 2-day course of postoperative antibiotics is noninferior to a standard 5-day course in patients with complex appendicitis. Here is an overview of the study:

- **Study design**: Multi-center, open-label, randomized controlled trial (RCT).
- **Population**: 1005 patients. Inclusion criteria included patients aged ≥ 8 years with complex appendicitis. Key exclusion criteria included no informed consent, interval appendectomy, clinical suspicion of severe sepsis, conservative treatment of acute appendicitis, immunocompromised state, and pregnancy.

- **Interventions**:
	- **Short 2-day course**: 502 patients received intravenous cefuroxime/metronidazole 1,500/500 mg thrice daily or ceftriaxone/metronidazole once daily 2,000 mg/500 mg thrice daily for 48 hours according to local antibiotic policy.
	- **Standard 5-day course**: 503 patients received intravenous cefuroxime/metronidazole 1,500/500 mg thrice daily or ceftriaxone/metronidazole once daily 2,000 mg/500 mg thrice daily for 5 days according to local antibiotic policy.

- **Primary outcome**: Difference not exceeding the non-inferiority margin in the rate of infectious complications and death within 90 days (10% vs. 8%; AD 2%, 95% CI -1.6 to 5.6).

- **Secondary outcomes**:
	- Significant increase in hospital readmission (12% vs. 6%; OR 2.135, 95% CI 1.34 to 3.4).
	- Significant decrease in adverse effects of antibiotics (9% vs. 22%; OR 0.344, 95% CI…).

---

### Continuous vs intermittent meropenem administration in critically ill patients with sepsis: The MERCY randomized clinical trial [^114dEQ2m]. JAMA (2023). High credibility.

The study MERCY was published by Giacomo Monti and colleagues in 2023 in the journal JAMA. This study is related to the following diseases: sepsis and septic shock. In the MERCY study, the trial question was: what is the role of continuous administration of meropenem in critically ill patients with sepsis? The study design was multi-center, double-blinded, and randomized controlled trial. The population consisted of 607 patients (203 female, 404 male).

- **Inclusion criteria**: Critically ill adult patients with sepsis or septic shock.
- **Key exclusion criteria**: Previous therapy with carbapenem antibiotics, very low probability of survival assessed using the Simplified Acute Physiology Score II, and severe immunosuppression.
- **Interventions**:
	- Continuous administration (3 g of meropenem administered over 24 hours, n = 303)
	- Intermittent administration (1 g of meropenem administered over 30–60 minutes every 8 hours, n = 304).
- **Primary outcome**: No significant difference in death from all causes and emergence of pandrug-resistant or extensively drug-resistant bacteria at day 28 (47% vs. 49%; RR 0.96, 96% CI 0.81 to 1.13).
- **Secondary outcomes**:
	- No significant difference in death at day 90 (42% vs. 42%; RR 1, 95% CI 0.83 to 1.21).
	- No significant difference in median days alive and free from antibiotics at day 28 (3 days vs. 2 days; MD 0.4, 95% CI -0.9 to 1.7).
	- No significant difference in median days alive and free from ICU at day 28 (0 days vs. 0 days; MD 0.6, 95% CI -1 to 2.2).

---

### Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial [^116wDHQj]. Lancet (2010). High credibility.

The study PRORATA was published in 2010 in the journal *Lancet*. This study addresses critical illness and focuses on whether a procalcitonin-guided strategy is noninferior to standard antibiotic treatment guidelines among ICU patients. The study design was a multi-center, open label, randomized controlled trial (RCT) involving 621 patients (210 female, 411 male).

- **Inclusion criteria**: Critically ill patients in ICU with suspected bacterial infections.
- **Key exclusion criteria**: Age < 18 years, known pregnancy, expected ICU stay < 3 days, bone-marrow transplant or chemotherapy-induced neutropenia, infections requiring long-term antibiotic treatment, and poor chance of survival.
- **Interventions**:
	- 307 patients were in the procalcitonin-guided antibiotic discontinuation group, following predefined algorithms for starting or discontinuing antibiotics based on serum procalcitonin concentrations.
	- 314 patients received usual care with antimicrobial treatment durations based on international and local guidelines.
- **Primary outcome**: Difference not exceeding the non-inferiority margin in death at day 28 (21.2% vs. 20.4%; AD 0.8%, 90% CI -4.6 to 6.2).
- **Secondary outcomes**:
	- Significant increase in days without antibiotics by day 28 (14.3 vs. 11.6; AD 2.7, 95% CI 1.4 to 4.1).
	- No significant difference in relapse (6.5% vs. 5.1%).
	- No significant difference in the number of days without mechanical ventilation.

---

### Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections [^115phhQJ]. The New England Journal of Medicine (2025). High credibility.

The BALANCE study was published by the BALANCE Investigators and colleagues in 2025 in the journal New England Journal of Medicine. This study is associated with several diseases: sepsis and septic shock, catheter-related bloodstream infection, acute pyelonephritis, acute appendicitis, acute diverticulitis, acute cholangitis, community-acquired pneumonia, hospital-acquired pneumonia, and cellulitis.

The trial question posed by the BALANCE study was whether antibiotic treatment for 7 days is noninferior to treatment for 14 days in hospitalized patients with a bloodstream infection. The study utilized a multi-center, open-label, randomized controlled trial (RCT) design. It included a population of 3608 patients, comprising 1686 females and 1922 males.

- **Inclusion criteria**: Hospitalized patients with bloodstream infection.

- **Key exclusion criteria**: Severe immunocompromised state, prosthetic heart valves or endovascular grafts, infectious syndromes requiring prolonged treatment, positive culture with a common contaminant, Staphylococcus aureus or Staphylococcus lugdunensis bacteremia, bacteremia from rare organisms requiring prolonged treatment, and fungemia.

- **Interventions**:
	- n = 1814 received 7-day antibiotic therapy (adequate antibiotic treatment for 7 days).
	- n = 1794 received 14-day antibiotic therapy (adequate antibiotic treatment for 14 days).

- **Primary outcome**: The primary outcome measured was the difference not exceeding the non-inferiority margin in the rate of death from any cause by 90 days after diagnosis (14.5% in the 7-day treatment group vs. 16.1% in the 14-day group; absolute risk difference -1.6, 95% CI -4 to 0.8).

- **Secondary outcomes**: There was no significant difference in dea.

---

### Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: The BLING III randomized clinical trial [^112KYsRG]. JAMA (2024). High credibility.

The study BLING III was published by Joel M. Dulhunty and colleagues in 2024 in the journal JAMA, focusing on sepsis and septic shock. The trial question addressed was whether continuous β-lactam antibiotic infusion is superior to intermittent β-lactam antibiotic infusion in critically ill patients with sepsis.

- **Study design**: Multi-center, open-label, randomized clinical trial (RCT).
- **Population**: 7,031 patients (2,423 female, 4,608 male). Inclusion criteria included critically ill adults treated with piperacillin/tazobactam or meropenem for sepsis. Key exclusion criteria included age < 18 years, antibiotic treatment > 24 hours during infection episode, pregnancy, allergy to piperacillin/tazobactam, meropenem, or penicillin, and receipt of renal replacement therapy (RRT).
- **Interventions**: Patients were randomized to receive either continuous infusion (n = 3,498) of piperacillin/tazobactam or meropenem over a 24-hour period, or intermittent infusion (n = 3,533) over a 30-minute period.
- **Primary outcome**: There was no significant difference in the rate of death within 90 days between the two groups (24.9% vs. 26.8%; OR 0.91, 95% CI 0.81 to 1.01).
- **Secondary outcomes**: A significant increase in clinical cure at day 14 was observed (55.7% vs. 50%; OR 1.26, 95% CI 1.15 to 1.38). There was no significant difference in the new acquisition, colonization, or infection with a multidrug-resistant organism or C. difficile infection at day 14 (7.2% vs. 7.5%; OR 0.96, 95% CI 0.8 to 1.15).

---

### Pathogen-targeted clinical development to address unmet medical need: Design, safety, and efficacy of the ATTACK trial [^1178CKBh]. Clinical Infectious Diseases (2023). High credibility.

Drug-resistant bacterial infections caused an estimated 4.95 million deaths worldwide in 2019. The continued global spread of antimicrobial resistance (AMR) has created an urgent need for novel antibiotics. Unfortunately, antibiotic discovery and development have not kept pace with the rapid evolution of AMR in bacterial pathogens. The problem of AMR is particularly concerning in *Acinetobacter baumannii* due to the limited number of therapeutic options against it. In the United States, investigators found that carbapenem-resistant *A. baumannii* causes approximately 1.2 cases per 100,000 persons, the vast majority of which occur among patients with exposure to a healthcare facility within the preceding year. *A. baumannii* has an extraordinary genetic plasticity that bestows a high capacity to acquire AMR traits, including against carbapenems. Among hospitalized patients, it is not uncommon to find multidrug-resistant (MDR; resistance to at least three classes of antimicrobials), extensively drug-resistant (XDR; MDR plus resistance to carbapenems), and pan-drug-resistant (XDR plus resistance to polymyxins) *A. baumannii* isolates, making them very challenging for clinicians to treat with our antibiotic armamentarium.

Historically, antimicrobial drug development has focused on discovering broad-spectrum agents that can be used as empiric therapy to treat serious infections. Clinical dogma is that broad-spectrum antibiotics are particularly important early in the course of an infection when the offending pathogen is not yet known. However, this approach encourages overprescription.

---

### What can we learn from differences in hospitals' sepsis care [^116CzB9u]. American Journal of Respiratory and Critical Care Medicine (2025). High credibility.

Sepsis remains a major cause of mortality and disability worldwide. Death certificate analyses suggest that sepsis accounts for at least one in five deaths globally. There is considerable variation in sepsis incidence and mortality between regions. Age-standardized sepsis mortality rate estimates are almost 20 times higher in sub-Saharan Africa than in Western Europe. Additionally, within regions, there is substantial variability: age-standardized mortality rates vary fourfold across Europe, ranging from 18.0 to 81.9 deaths per 100,000 persons in Finland and Moldova, respectively.

The considerable variability in sepsis mortality rates within and between regions raises the question, "Why?" Is the variability due to differences in patient factors (comorbidities, infection types, pathogens, etc), infrastructure (distance to hospital, hospital services, etc), or care factors (sepsis screening and recognition, time to antibiotics, fluid resuscitation, etc)? A comprehensive survey on sepsis care in over 1,000 hospitals, mainly in Europe and published in this issue of the journal, provides welcome insight into differences in sepsis infrastructure and care protocols within Europe.

The European Sepsis Care Survey was a voluntary survey organized by the European Sepsis Alliance to assess hospitals' adoption of Surviving Sepsis Campaign guideline recommendations and their infrastructure to support sepsis care. The survey was conducted between August 2021 and June 2022. Responses were received from 1,023 hospitals, 82% of which were in Europe. The authors identified substantial variability in sepsis care practices and infrastructure among these hospitals, highlighting key areas for improvement and standardization.

---

### Avycaz [^114TZJkx]. U.S. Food and Drug Administration (2025). High credibility.

In the AVYCAZ and meropenem treatment groups, up to 26% of patients received more than 24 hours of potentially effective systemic Gram-negative antibacterial therapy in the three days prior to randomization. Patients with infections only due to Gram-positive organisms were excluded from the trial when this could be determined before enrollment. Following randomization, patients in both treatment groups could receive empiric open-label linezolid or vancomycin to cover for Gram-positive pathogens while awaiting culture results. Treatment with Gram-positive coverage continued in patients with Gram-positive pathogens.

Adjunctive Gram-negative antibacterial therapy with amikacin or another aminoglycoside was permitted if resistance to meropenem was suspected. Systemic Gram-negative antibacterial therapy was administered to 87% and 86% of patients in the AVYCAZ and meropenem treatment groups, respectively, at any point up to the end of therapy. In either treatment group, up to 36% of patients received more than 72 hours of potentially effective concomitant therapy.

- **28-day all-cause mortality rates**: Table 23 presents the 28-day all-cause mortality rates (28 to 32 days after randomization). Results are presented for the ITT population and for the microbiological intent-to-treat (micro-ITT) population, which included all patients with positive culture results indicating the presence of at least one Gram-negative pathogen. Clinical cure at the TOC visit (21–25 days from randomization) is also presented. Clinical cure was defined as resolution or significant improvement in signs and symptoms associated with pneumonia.

---

### Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: The ACORN randomized clinical trial [^111taGXA]. JAMA (2023). High credibility.

The ACORN study, published by Edward T. Qian and colleagues in 2023 in the journal JAMA, focuses on various diseases related to acute infections:

- **Sepsis-related conditions**: Sepsis, septic shock
- **Abdominal infections**: Lung abscess, acute cholangitis, acute cholecystitis, acute diverticulitis, acute pancreatitis, acute mesenteric ischemia, spontaneous bacterial peritonitis, intra-abdominal abscess
- **Genitourinary infections**: Acute pyelonephritis
- **Skin and bone infections**: Cellulitis, surgical site infection, vertebral osteomyelitis, nonvertebral osteomyelitis, septic arthritis
- **Respiratory infections**: Community-acquired pneumonia, ventilator-associated pneumonia, hospital-acquired pneumonia
- **Other infections**: Penetrating abdominal trauma, antimicrobial-resistant Gram-negative infections

The trial aimed to determine the role of cefepime in patients hospitalized with acute infection. It was designed as a single-center, open-label randomized clinical trial (RCT) involving 2,511 patients (1,071 female, 1,440 male). The inclusion criteria included adult patients needing antipseudomonal antibiotics within 12 hours of hospital presentation, either in the emergency department or ICU. Key exclusion criteria were allergies to cephalosporins or penicillins and receipt of more than one dose of antipseudomonal cephalosporin or penicillin within the previous seven days.

Interventions included cefepime: n = 1,214 (IV 2 g every 8 hours) and piperacillin/tazobactam: n = 1,297 (IV 3.375 g every 8 hours). The primary outcome showed no significant difference in the rate of stage 3 acute kidney injury (AKI) or death by day 14 (14.6% vs. 13.5%; OR 0.95, 95% CI 0.8 to 1.13).

---

### The foundation for the National Institutes of Health Biomarkers Consortium: Past accomplishments and new strategic direction [^113Vr11F]. Clinical Pharmacology and Therapeutics (2019). Low credibility.

A strong example of an impactful project that has resulted in direct benefit to patients and improved standards of care is evident from the results of the BC projects in community-acquired bacterial pneumonia (CABP), acute skin and skin structure infection (ABSSSI), hospital-acquired bacterial pneumonia (HABP), and ventilator-associated bacterial pneumonia (VABP).

Due to increasing antibiotic resistance, many bacterial infections are very difficult to treat, and new antibiotics are urgently needed to save patient lives. The traditional measures of treatment success in clinical trials of antibiotics for skin infections and pneumonia have not kept pace with the evolving standards of regulatory science, leading to substantial uncertainty and delays for companies developing these important drugs. Historically, efficacy endpoints for antibiotic registrational trials were based on resolution or improvement of signs and symptoms of infection at a time point after completion of therapy. By design, these endpoints included assessments at earlier time points as an element of outcome. As novel drug development understanding moved forward, the FDA and the scientific community realized that the design of noninferiority trials evaluating antibiotics could be improved by defining more reliable outcome measures that reduced dependence on subjective elements and by evaluating outcomes at time points for which prior evidence had demonstrated well-defined, reliable, and reproducible drug effects.

---

### Electronic prescribing: Reducing delay to first dose of antibiotics for patients in intensive care [^117D3LoM]. BMJ Quality Improvement Reports (2014). Low credibility.

The Surviving Sepsis Campaign advocates the use of the "resuscitation care bundle", a package of interventions providing a structured approach to managing sepsis. Sepsis is commonly defined as a systemic inflammatory response syndrome (SIRS) arising as a consequence of infection; this escalates to "severe sepsis" if associated with organ dysfunction, hypotension, or tissue hypoperfusion. One component of the resuscitation care bundle is the timely administration of appropriate antibiotics, based on evidence that prompt initiation of antibiotics improves survival in septic shock. Surviving Sepsis guidelines recommend that the first antibiotic dose should be given within an hour of presentation to patients with severe sepsis.

The research team set out to evaluate the role of our electronic prescribing (EP) system in administering antibiotics to patients with severe sepsis in an Intensive Care Unit (ICU) environment. It was hypothesized that some delays in antibiotic administration might be attributable to the default dose timings implemented by the EP system and that simple modifications to the EP protocol might reduce such delays.

The team's performance in achieving antibiotic administration within an hour of the prescription being generated was audited by retrospectively reviewing cases before and after the implementation of EP modifications. Overall, this study aims to inform the introduction and ongoing use of EP for antibiotic prescriptions in critical care and emergency settings.

---

### Adult cancer clinical trials that fail to complete: An epidemic [^111sjHEb]. Journal of the National Cancer Institute (2014). Low credibility.

The number and diversity of cancer therapeutics in the pipeline have increased over the past decade due to an enhanced understanding of cancer biology and the identification of novel therapeutic targets. At the same time, the cost of bringing new drugs to market and the regulatory burdens associated with clinical drug development have progressively increased. The finite number of eligible patients and limited financial resources available to evaluate promising new therapeutics represent rate-limiting factors in the effort to translate preclinical discoveries into the next generation of standard therapeutic approaches.

Optimal use of resources requires understanding and ultimately addressing inefficiencies in the cancer clinical trials system. Prior analyses have demonstrated that a large proportion of trials initiated by the National Cancer Institute (NCI) Cooperative Group system are never completed. While NCI Cooperative Group trials are important, they represent only a small proportion of all cancer clinical trials performed.

Herein, we explore the problem of cancer clinical trials that fail to complete within the broader cancer clinical trials enterprise. Among 7776 phase II-III adult cancer clinical trials initiated between 2005–2011, we found a seven-year cumulative incidence of failure to complete of approximately 20% (95% confidence interval = 18% to 22%). Nearly 48000 patients were enrolled in trials that failed to complete. These trials likely contribute little to the scientific knowledge base, divert resources and patients from answering other critical questions.

---

### The crisis of no new antibiotics — what is the way forward [^114wwDRV]. The Lancet Infectious Diseases (2012). High credibility.

Antibiotic use not only underpins modern medicine, but has brought huge changes to the world, especially in expectations of survival of children into adulthood. The theme of World Health Day 2011 was "antimicrobial resistance: no action today and no cure tomorrow". The demise of antibacterial drug discovery brings the spectre of untreatable infections. To prevent this crisis, immediate action is needed, and a new initiative, Antibiotic Action, has been launched. By bringing together communities who need these drugs with academia, health-care professionals, and pharmaceutical companies, this initiative aims to strengthen and enhance academic-industrial partnerships, revise the costly and laborious processes of licensing and regulation of new antibiotics, and address the economics of antimicrobial drugs (cost of use vs. profit). A global alliance for antibiotic drug discovery and development would provide a platform for these initiatives.

---

### Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: A perspective from COMBACTE's STAT-Net [^114svqu1]. Intensive Care Medicine (2017). Low credibility.

Discussions on the most appropriate endpoints for RCTs in severely ill patients leave developers in an uncertain position when designing new trials. First of all, if consensus is not reached, future reviews and meta-analyses will not be able to bring together information on new therapies, as the clinical data and evaluated endpoints will differ. Secondly, it postpones discussions about how to handle the transition period from old to new endpoints. In this era of rising resistance levels, slowly refilling antibiotic development pipelines, and an aging population, we need to make sure that RCTs effectively and validly determine the added benefit of new antibiotic agents, especially for severely ill patients. Regulatory authorities, pharmaceutical companies, and clinical investigators need to agree soon on the most appropriate clinical endpoints for this vulnerable patient group in order to ensure that new, effective antibiotic agents will become available for medical prescription efficiently and that unnecessary deaths can be avoided.

---

### Progress in the fight against multidrug-resistant bacteria 2005–2016: Modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance [^112eBS6o]. Clinical Infectious Diseases (2017). Low credibility.

In a noninferiority trial, active treatments are compared with the knowledge that sufficiently similar response rates will permit a conclusion that clinically relevant differences in efficacy are very unlikely. Critical design elements for robust noninferiority trials include (1) disease definitions that identify patients with an acute, severe infection that requires antibiotic therapy, (2) a reliable and reproducible endpoint, and (3) data showing a benefit of active antibiotic therapy over placebo. Recently, these elements have been refined for six well-characterized acute, severe bacterial infections: acute bacterial skin and skin structure infection, community-acquired bacterial pneumonia, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, complicated intra-abdominal infection, and complicated urinary tract infection.

- **The 6 types of severe infection recommended for general antibacterial development**: The focus on these specific infections is an important evidence-based element underpinning the use of noninferiority designs for new agent registration. Although some have noted that, for example, skin infection is not the most important potential use for a new antistaphylococcal agent, or that inclusion of outpatients suggests that patients lacked a life-threatening infection, such arguments fail to recognize that (1) patients meeting the definitions of new regulatory guidance have a severe infection that will have a poor outcome without efficacious antibiotic therapy and (2) initial registration based on o

---

### An update on management of adult patients with acute respiratory distress syndrome: An official American Thoracic Society clinical practice guideline [^112CEtUu]. American Journal of Respiratory and Critical Care Medicine (2024). High credibility.

Development of clinical recommendations: Each group convened to develop initial recommendations for the individual PICO questions. The co-chairs and methodologists led the groups through a discussion of the evidence profiles and GRADE Evidence to Decision framework to determine the direction and strength of the recommendations (see online supplement). As part of the GRADE Evidence to Decision process, we considered several factors including the certainty of evidence, the balance of desirable and undesirable consequences of an intervention, patient preferences and values, resource use, implications for health equity, acceptability of the intervention to stakeholders, and clinical feasibility.

Evidence across the full spectrum of ARDS severity was unavailable for some interventions. For these interventions, recommendations were limited to the specific severity subgroups (i.e. mild, moderate, or severe) for which evidence was sufficient, and no recommendation was made for subgroups lacking sufficient evidence. Each recommendation was designated as "strong" or "conditional".

After the individual groups generated draft recommendations, these were presented to the full panel for detailed discussion, input, and approval. Final recommendations were determined by the consensus of the full panel. Consistent with the GRADE approach, voting was planned for recommendations that could not achieve consensus through discussion; however, this was not required.

- **Manuscript preparation**: The writing committee, composed of the chairs and co-chairs, took responsibility for drafting the document for publication.

---

### Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis [^1178vKFZ]. Intensive Care Medicine (2016). High credibility.

The study BLISS was published in 2016 in the journal Intensive Care Medicine, focusing on sepsis and septic shock. The trial investigated the role of continuous infusion of β-lactam antibiotics in critically ill patients with severe sepsis who were not receiving renal replacement therapy (RRT).

The study design was a multi-center, open-label, randomized controlled trial (RCT) involving 140 patients (44 females, 96 males). Inclusion criteria encompassed critically ill patients with severe sepsis not undergoing RRT. Key exclusion criteria included receipt of RRT, impaired hepatic function, receipt of palliative treatment, inadequate central venous catheter access, and imminent death.

- **Interventions**:
	- n = 70 received continuous β-lactam antibiotics (continuous infusion of β-lactam antibiotics).
	- n = 70 received intermittent β-lactam antibiotics (intermittent bolus dosing of β-lactam antibiotics).

- **Primary outcome**: A significant increase in clinical cure was observed 14 days after antibiotic cessation (56% vs. 34%; absolute difference (AD) 22%, 95% confidence interval (CI) -0.4 to -0.1).

- **Secondary outcomes**:
	- A significant increase in the rate of plasma antibiotic concentrations measured at 100% of the dosing interval on day 3 (97% vs. 68%; AD 29%, 95% CI -0.4 to -0.1).
	- No significant difference in ventilator-free days (22 days vs. 14 days; AD 8 days, 95% CI -2 to 18).
	- No significant difference in ICU-free days (20 days vs. 17 days; AD 3 days, 95% CI -3 to 9).

- **Safety outcomes**: No specific safety outcomes were detailed, but adverse events were monitored throughout the study period.

---

### Pharmacological treatments in ARDS; a state-of-the-art update [^113UHJ4Z]. BMC Medicine (2013). Low credibility.

Despite many interventions being studied, at the time of writing, there has been little success in developing effective pharmacological therapies for the management of ARDS. However, given the high associated morbidity and mortality, there is pressure to continue efforts to improve outcomes. Increasing numbers of pharmacological therapies are being investigated, and with encouraging pre-clinical and early clinical results, it is expected that over the coming years, some will develop into useful agents for the prevention and treatment of ARDS.

---

### Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment [^112JoHKU]. Critical Care Medicine (2005). Low credibility.

To provide further evidence for the efficacy and safety of drotrecogin alfa (activated) treatment in severe sepsis, a single-arm, open-label trial was conducted.

Enrollment began in March 2001, and day-28 follow-up was completed in January 2003. ENHANCE took place in 25 countries at 361 sites. Patients included those with known or suspected infection, three or four systemic inflammatory response syndrome criteria, and one or more sepsis-induced organ dysfunctions. Of the 2,434 adults entered, 2,378 received drotrecogin alfa (activated), and 2,375 completed the protocol. The intervention involved the infusion of drotrecogin alfa (activated) at a dose of 24 µg/kg/hr for 96 hours.

- **Measurements and main results**: The 28-day all-cause mortality rate approximated that observed in the PROWESS trial (25.3% vs. 24.7%). Patients in ENHANCE experienced increased serious bleeding rates compared with those in the drotrecogin alfa (activated) arm of PROWESS (during infusion, 3.6% vs. 2.4%; post-infusion, 3.2% vs. 1.2%; 28-day, 6.5% vs. 3.5%). Increased post-infusion bleeding suggested a higher background bleeding rate. Intracranial hemorrhage was more common in ENHANCE than in PROWESS (during infusion, 0.6% vs. 0.2%; 28-day, 1.5% vs. 0.2%). The incidence of fatal intracranial hemorrhage was the same during infusion (0.2%) and higher at 28 days (0.5% vs. 0.2%). ENHANCE patients treated within 0–24 hours from their first sepsis-induced organ dysfunction exhibited a lower observed mortality rate than those treated after 24 hours (22.9% vs. 27.4%, p = .01).

---

### A randomized trial comparing antibiotics with appendectomy for appendicitis [^112TEPjG]. The New England Journal of Medicine (2020). High credibility.

The study CODA, published by CODA Collaborative and colleagues in 2020 in the journal New England Journal of Medicine, investigated acute appendicitis. The trial question was whether antibiotic therapy is noninferior to appendectomy in patients with appendicitis. This multi-center, open-label randomized controlled trial (RCT) included 1,552 patients (576 female, 976 male), with adult patients with appendicitis as the population.

- **Inclusion criteria**: Adult patients with appendicitis.
- **Exclusion criteria**: Septic shock, diffuse peritonitis, re-appendicitis, severe phlegmon on imaging, walled-off abscess, free air or more than minimal free fluid, and evidence suggestive of neoplasm.

- **Interventions**:
	- **Antibiotics**: 776 patients received intravenous antibiotics for 24 hours followed by oral antibiotics for 10 days.
	- **Appendectomy**: 776 patients received appendectomy using laparoscopic and conventional surgical approaches.

- **Primary outcome**: The primary outcome was the difference not exceeding the non-inferiority margin in mean improvement in health status at day 30, as measured by the European QoL-5 dimension questionnaire score (0.92 points vs. 0.91 points; mean difference 0.01, 95% CI 0 to 0.03).

- **Secondary outcomes**:
	- No significant difference in resolution of symptoms at day 30 (68% vs. 70%; risk ratio 0.97, 95% CI 0.91 to 1.04).
	- Significant increase in the rate of emergency department or urgent care clinic visits after the index treatment within 90 days (9% vs. 4%; risk ratio 2.07, 95% CI 1.32 to 3.25).

No significant difference was observed in the days from randomization to discharge for the index treatment.

---

### Protocolised management in sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock [^1169UN6R]. Health Technology Assessment (2015). High credibility.

The study ProMISe, published in 2015 in the journal Health Technology Assessment, relates to the diseases sepsis and septic shock. The trial investigated the effect of early goal-directed therapy for the resuscitation of patients presenting with early septic shock. This multi-center, open-label, randomized controlled trial included a population of 1,260 patients (532 female, 728 male). Patients presenting with early septic shock were included, while key exclusion criteria were age over 90 or under 18 and pregnancy.

- **Intervention and Comparator**:
	- Early goal-directed therapy involved standardized resuscitation with specific monitoring and target objectives (central venous pressure > 8 mmHg, mean arterial pressure > 65 mmHg, ScvO₂ > 70%) for 630 patients.
	- Usual care decisions were at the discretion of the treating clinician for the remaining 630 patients.

- **Primary outcome**: No significant difference in death at 90 days was observed (29.5% vs. 29.2%; RR 1.01, 95% CI 0.85 to 1.2).

- **Secondary outcomes**: A borderline significant decrease in quality-adjusted life years was noted (4.584 vs. 4.582; ARR 0.002, 95% CI -0.41 to 0.41). There was no significant difference in lifetime cost per patient (£33,620 vs. £32,142; AD £1,478, 95% CI -£1,434 to £4,390).

- **Safety outcomes**: There was no significant difference in adverse events.

---

### Designing development programs for non-traditional antibacterial agents [^1114yC9N]. Nature Communications (2019). Low credibility.

If a non-inferiority study is designed such that (a) the dose of the novel agent is chosen to maximize its likely efficacy based on preclinical data and (b) individuals failing either study arm are promptly moved to a salvage therapy, the risk of inadequately treated infection or rapid progression would be addressed, and the risk of serious harm to study subjects minimized. Thus, it would be possible to comply with the ethical standard espoused in the Good Clinical Practice guidelines, specifically Point 2.3 of ICH E6 (R1), which states that the "rights, safety, and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society".

Risks to individual trial participants are often justified by the prospect of benefit that would accrue only or primarily to future patients. Indeed, Miller and Joffe argue that "risk–benefit assessment, geared to the purpose of clinical trials in developing knowledge to inform health-policy decisions for populations of patients", is more important to assessing a trial's ethical permissibility than the presence of equipoise as traditionally understood. Moreover, U.S. regulations governing research with human subjects explicitly acknowledge that study risks and benefits may not necessarily accrue to the same individuals. These regulations permit Institutional Review Boards to approve proposed research when "[r]isks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result".

---

### (1 → 3)-β-D-glucan-guided antifungal therapy in adults with sepsis: The CandiSep randomized clinical trial [^113xBz35]. Intensive Care Medicine (2022). High credibility.

The CandiSep study, published in 2022 in the journal Intensive Care Medicine, addresses the role of (1,3)-β-D-glucan-guided antifungal therapy in patients with sepsis at high risk for invasive candidiasis. This multi-center, open-label randomized clinical trial involved 342 patients (120 female, 222 male) with sepsis at high risk for invasive Candida infection.

Inclusion criteria included adult patients with sepsis at high risk for invasive Candida infection. Key exclusion criteria were proven invasive Candida infection, systemic antifungal therapy prior to inclusion, liver cirrhosis of Child-Pugh class C, recent treatment with immunoglobulins, and immunosuppression.

- **Interventions**:
	- **(1,3)-β-D-glucan guidance**: 173 patients received antifungals if at least one of two consecutive (1,3)-β-D-glucan samples taken during the first two study days measured ≥ 80 pg/mL.
	- **Standard care**: 169 patients received targeted antifungal therapy driven by culture results.

- **Primary outcome**:
	- No significant difference in death at day 28 (33.7% vs. 30.5%; RR 1.1, 95% CI 0.8 to 1.51).

- **Secondary outcomes**:
	- No significant difference in death in the hospital (34.5% vs. 35.9%; RR 0.96, 96% CI 0.71 to 1.29).
	- Significant increase in antifungal-free survival at day 28 (30.2% vs. 52.1%; RR 2.97, 95% CI 2.1 to 4.2).
	- Significant decrease in time to antifungal therapy (1.1 days).

---

### The United Kingdom paediatric critical care society study group: The 20-year journey toward pragmatic, randomized clinical trials [^1176RhEm]. Pediatric Critical Care Medicine (2022). Low credibility.

Over the past two decades, pediatric intensive care research networks have been formed across North America, Europe, Asia, and Australia/New Zealand. The U.K. Paediatric Critical Care Society Study Group (PCCS-SG) has over a 20-year tradition of fostering collaborative research, leading to the design and successful conduct of randomized clinical trials (RCTs). At the time of writing, the PCCS-SG network has delivered 13 different multicenter RCTs, covering a spectrum of study designs, methodologies, and scale. Lessons from the early years have led PCCS-SG to now focus on the entire process needed for developing an RCT, starting from robust preparatory steps such as surveys, data analysis, and feasibility work through to a definitive RCT. Pilot RCTs have been an important part of this process as well.

Facilitators of successful research have included the presence of a national registry to facilitate efficient data collection; close partnerships with established Clinical Trials Units to bring together clinicians, methodologists, statisticians, and trial managers; greater involvement of transport teams to recruit patients early in trials of time-sensitive interventions; and the funded infrastructure of clinical research staff within the National Health Service to integrate research within the clinical service. The informal nature of PCCS-SG has encouraged buy-in from clinicians. Greater international collaboration and development of embedded trial platforms to speed up the generation and dissemination of trial findings are two key future strategic goals for the PCCS-SG research network.

---

### Dalvance [^116icpxT]. U.S. Food and Drug Administration (2025). High credibility.

Clinical trials experience:

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of Dalvance cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice.

- **Clinical trials experience in adult patients**: Adverse reactions were evaluated for 2,473 patients treated with Dalvance. Out of these, 1,778 patients were treated with Dalvance in seven Phase 2/3 trials comparing Dalvance to comparator antibacterial drugs, and 695 patients were treated with Dalvance in one Phase 3 trial comparing Dalvance single and two-dose regimens. The median age of patients treated with Dalvance was 48 years, ranging between 16 and 93 years. Patients treated with Dalvance were predominantly male (59.5%) and White (81.2%).

- **Serious adverse reactions and adverse reactions leading to discontinuation**: Serious adverse reactions occurred in 121/2,473 (4.9%) of patients treated with any regimen of Dalvance. In the Phase 2/3 trials comparing Dalvance to comparator, serious adverse reactions occurred in 109/1,778 (6.1%) of patients in the Dalvance group and 80/1,224 (6.5%) of patients in the comparator group. In a Phase 3 trial comparing Dalvance single and two-dose regimens, serious adverse reactions occurred in 7/349 (2.0%) of patients in the Dalvance single-dose group and 5/346 (1.4%) of patients in the Dalvance two-dose group. Dalvance was discontinued due to an adverse reaction in 64/2,473 (2.6%) of patients treated with any regimen of Dalvance.

---

### Evidence at time of regulatory approval and cost of new antibiotics in 2016–19: cohort study of FDA approved drugs [^112m88ew]. BMJ Medicine (2022). High credibility.

Since the discovery of antibiotics almost a century ago, bacteria have acquired antibiotic resistance by various means. According to the Centers for Disease Control and Prevention (CDC), every year at least 2.8 million people in the US are infected with bacteria resistant to at least one antibiotic. Antibiotic resistance, associated with more than 35,000 deaths annually, is a public health problem, particularly for infections caused by Gram-negative bacteria. A vibrant development pipeline of new interventions to treat infections and improve patient outcomes is needed.

In recent years, however, antibiotic development has slowed. Between 1990 and 2000, the US Food and Drug Administration approved 21 new antibiotics compared with six in 2000–10. Some have criticized the substantial testing required of new antibiotics to justify regulatory approval by the FDA. Large pharmaceutical manufacturers have left antibiotic development, citing the high cost of development and the limited returns on drugs, at least compared with other disciplines, such as cancer treatments. Also, when new antibiotics are approved, low uptake has been reported.

Legislators in the US have enacted multiple approaches to enhance the antibiotic development pipeline. The Generating Antibiotic Incentives Now (GAIN) Act of 2012 provided a five-year extension on guaranteed protection from the entry of generic drugs for new antibiotics that treat multidrug-resistant bacterial infections. The act also made antibacterial and antifungal drugs with in vitro activity against resistant or other qualifying pathogens eligible for additional incentives.

---

### Improving empiric antibiotic selection for patients hospitalized with abdominal infection: The INSPIRE 4 cluster randomized clinical trial [^116x9uNy]. JAMA Surgery (2025). High credibility.

Empiric extended-spectrum antibiotics are routinely prescribed for over a million patients hospitalized annually with abdominal infection despite low likelihoods of infection with multidrug-resistant organisms (MDROs).

- **Objective**: To evaluate whether computerized provider order entry (CPOE) prompts providing patient- and pathogen-specific MDRO infection risk estimates can reduce empiric extended-spectrum antibiotics for non-critically ill patients admitted with abdominal infection.

- **Design, setting, and participants**: This 92-hospital cluster randomized clinical trial assessed the effect of an antibiotic stewardship bundle with CPOE prompts versus routine stewardship on antibiotic selection during the first three hospital days (empiric period) in non-critically ill adults hospitalized with abdominal infection. The trial population included adults (≥ 18 years) treated with empiric antibiotics for abdominal infection in non-intensive care units (ICUs). The trial periods included a 12-month baseline from January to December 2019 and an intervention period from January to December 2023.

- **Intervention**: CPOE prompts recommended standard-spectrum antibiotics in patients prescribed extended-spectrum antibiotics during the empiric period if the patient's estimated absolute risk of MDRO abdominal infection was less than 10%, coupled with feedback and education.

- **Main outcomes and measures**: The primary outcome was empiric extended-spectrum antibiotic days of therapy. Safety outcomes included days to ICU transfer and hospital length of stay. Analyses compared differences between the baseline and intervention periods.

---

### Surviving sepsis campaign research priorities 2023 [^111j6k7T]. Critical Care Medicine (2024). High credibility.

To identify research priorities in the management, epidemiology, outcomes, and pathophysiology of sepsis and septic shock, a multiprofessional group of 16 international experts formed the Surviving Sepsis Research Committee. This committee, representing the European Society of Intensive Care Medicine and the Society of Critical Care Medicine, convened virtually shortly after publishing the most recent Surviving Sepsis Campaign Guidelines. The group iteratively developed the article and recommendations, providing an update from the 2018 Surviving Sepsis Campaign Research Priorities.

Each task force member submitted five research questions on any sepsis-related subject. Committee members then independently ranked their top three priorities from the generated list. The highest-rated clinical and basic science questions were developed into the article.

A total of 81 questions were submitted. After merging similar questions, 34 clinical and ten basic science research questions were submitted for voting.

- **Top clinical priorities**:
	1. What is the best strategy for screening and identifying patients with sepsis, and can predictive modeling assist in real-time recognition of sepsis?
	2. What causes organ injury and dysfunction in sepsis, how should it be defined, and how can it be detected?
	3. How should fluid resuscitation be individualized initially and beyond?
	4. What is the best vasopressor approach for treating the different phases of septic shock?
	5. Can a personalized/precision medicine approach identify optimal treatments?

---

### Novel approaches are needed to develop tomorrow's antibacterial therapies [^111yzzKR]. American Journal of Respiratory and Critical Care Medicine (2015). Low credibility.

Society faces a crisis of rising antibiotic resistance even as the pipeline of new antibiotics has been drying up. Antibiotics are a public trust; every individual's use affects their efficacy for everyone else. As such, responses to the antibiotic crisis must take a societal perspective. The market failure of antibiotics is due to a combination of scientific challenges in discovering and developing new antibiotics, unfavorable economics, and a hostile regulatory environment.

- **Scientific solutions**: Include changing the way we screen for new antibiotics. More transformationally, developing new treatments that seek to disarm pathogens without killing them, or that modulate the host inflammatory response to infection, will reduce selective pressure and hence minimize resistance emergence.

- **Economic transformation**: Will require new business models to support antibiotic development.

- **Regulatory reform**: Is needed so that clinical development programs are feasible, rigorous, and clinically relevant. Pulmonary and critical care specialists can have a tremendous impact on the continued availability of effective antibiotics.

Encouraging the use of molecular diagnostic tests to allow pathogen-targeted, narrow-spectrum antibiotic therapy, using short rather than unnecessarily long courses of therapy, reducing inappropriate antibiotic use for probable viral infections, and reducing infection rates will help preserve the antibiotics we have for future generations.

---

### Advancing pediatric antibacterial drug development: A critical need to reinvent our approach [^114UqxUV]. Journal of the Pediatric Infectious Diseases Society (2019). Low credibility.

The Clinical Trials Transformation Initiative convened with several groups in the pediatric antibacterial drug development community to identify challenges and recommend ways to improve practice. Attention to five major areas holds the promise of making new antibiotics available for use in children as soon as possible after their approval for use in adults.

---

### Advancing pediatric antibacterial drug development: A critical need to reinvent our approach [^1172WFBV]. Journal of the Pediatric Infectious Diseases Society (2019). Low credibility.

The Clinical Trials Transformation Initiative convened with several groups in the pediatric antibacterial drug development community with the goal of identifying challenges and recommending ways to improve practice. Attention to five major areas holds the promise of making new antibiotics available for use in children as soon as possible after they are approved for use in adults.

---

### Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: Implications for future clinical trial study design [^115GLJ7N]. Clinical Infectious Diseases (2008). Low credibility.

Regulatory uncertainty has led to the cessation of antimicrobial agent drug development for some community-acquired respiratory tract infections. This uncertainty stems from the fact that many people, including individuals within the government, are unsure about the magnitude of drug effect relative to no treatment in patient populations perceived to be at low-to-moderate risk of mortality. Without such information, it is not possible to power noninferiority studies, which, in turn, necessitates the need for superiority study designs.

Moreover, many believe that categorical clinical trial endpoints (success or failure), determined 7–14 days after therapy, are insensitive measures of drug benefit and that new outcome measures are needed. At the time of writing, characterization of the magnitude of treatment effect relative to that of no treatment has not been accomplished through traditional examinations of existing clinical trial databases or evaluations of historical data. However, pharmacokinetic-pharmacodynamic analyses of existing clinical trial data may provide a new context to inform the debate.

Herein, we examine pharmacokinetic-pharmacodynamic relationships for efficacy derived from recent clinical drug development programs involving agents for the treatment of community-acquired respiratory tract infections. Through a collective understanding of these data, it may be possible to estimate the no-treatment response rate without exposing patients to any risk incurred by conducting clinical trials with alternative designs (e.g. placebo-controlled studies).

---

### Avycaz [^113VC7vs]. U.S. Food and Drug Administration (2025). High credibility.

The administration of prior or concomitant Gram-negative antibacterial therapy can confound the assessment of trial results. However, a subgroup analysis of 28-day all-cause mortality in subjects who received 24 hours or less of potentially effective antibacterial therapy prior to randomization and 72 hours or less of concomitant potentially effective antibacterial therapy following randomization produced results similar to the overall ITT population, with AVYCAZ mortality at 10.0% (20/200) and meropenem at 6.2% (12/195) [difference 3.8%; 95% CI: -1.6% to 9.5%].

In the subset of patients who received more than 24 hours of potentially effective antibacterial therapy prior to randomization or more than 72 hours of concomitant potentially effective antibacterial therapy following randomization, results were similar to the overall ITT population (AVYCAZ 9.7% (25/258), meropenem 10.5% (28/266) [difference -0.08%; 95% CI: -6.1% to 4.4%]).

All-cause mortality rates by pathogen are presented in Table 24. Of the 382 patients in the micro-ITT population, 36 patients were bacteremic at baseline; 20/21 (95.2%) in the AVYCAZ arm and 13/15 (86.7%) in the meropenem arm survived through the day-28 follow-up visit. Additionally, 13/21 (61.9%) patients in the AVYCAZ arm and 9/15 (60%) of patients in the meropenem arm had a clinical cure at the TOC visit.

---

### Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021 [^111pBMvP]. Intensive Care Medicine (2021). High credibility.

Regarding medical management for sepsis and septic shock, more specifically with respect to antimicrobial therapy (choice of antifungal agent), the SSC 2021 guidelines recommend considering the initiation of empiric antifungal therapy in adult patients with sepsis or septic shock who are at high risk of fungal infection.

---

### The antibiotic R&D pipeline: an update [^113fWeuL]. Current Opinion in Microbiology (2011). Low credibility.

There is an urgent need for new antibacterials to target emerging multidrug-resistant bacteria. The demand for such agents is increasing, while efforts in antibacterial research have declined dramatically over the past few decades. As a result, only four compounds belonging to new chemical classes have been approved for clinical use. The main reasons leading to this critical situation are briefly described. A renewed interest in research on new effective antimicrobials is nonetheless delivering compounds derived mainly from the modification of existing drugs, though new chemical classes are appearing. Because many of these activities have started relatively recently, we should expect a long period before new antibiotics are added to the medical armamentarium.

---

### Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: A perspective from COMBACTE's STAT-Net [^112e9nyk]. Intensive Care Medicine (2017). Low credibility.

Use of well-defined outcomes to assess clinical trial results is of major importance. Ideally, endpoints in clinical trials for novel antibiotic agents should be objective, reproducible, have high internal and external validity, and be clinically meaningful: a direct measure of how patients feel, function, and survive. Unfortunately, at the moment, there is a lack of universal, well-accepted endpoints, particularly for severe hospital-acquired infections. This has resulted in inconsistencies in how trials are designed and reported, raising questions about internal validity and making interpretations across trials difficult.

A recent Delphi process to define standardized endpoints for trials on antibiotic therapy for bloodstream infections (BSIs) identified that no well-validated primary endpoints existed; mortality or clinical cure, at hospital discharge or up to 12 weeks after treatment, were the most common primary endpoints. As another example, the US Food and Drug Administration (FDA) recommends all-cause mortality as the primary efficacy endpoint for trials on hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), whereas the European Medicines Agency recommends clinical outcome at the test of cure visit for these types of infectious syndromes.

At the same time, both cure and mortality endpoints have challenges associated with them, especially in critically ill patients. First, in this group of patients, cure is very difficult to define since clinical signs an

---

### The Overton window and a less dogmatic approach to antibiotics [^112nSw4W]. Clinical Infectious Diseases (2020). Low credibility.

This analysis summarizes a set of recent, innovative trials in infectious diseases that redefine previous, non-evidence-based "rules" for antibiotics. Recent trials in infectious diseases have led to reconsidering the traditional treatment of infectious diseases by changing the duration or type of traditional antibiotics or evaluating new antibiotics for approval. These trials have used the noninferiority trial approach. The noninferiority trial design and recent infectious disease trials of relevance are discussed in this viewpoint. My objective was to analyze recent trials in infectious disease and consider needs for future trials.

---

### Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012 [^114qFyMu]. Critical Care Medicine (2013). High credibility.

To provide an update to the "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock", last published in 2008, a consensus committee of 68 international experts representing 30 organizations was convened. Nominal groups were assembled at key international meetings for those members attending the conference. A formal conflict of interest policy was established and enforced throughout the process. The guidelines development was conducted independently of industry funding. A stand-alone meeting was held for subgroup heads, co- and vice-chairs, and selected individuals. Teleconferences and electronic discussions among subgroups and the entire committee were integral to the development.

The authors followed the principles of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. This guided the assessment of evidence quality from high (A) to very low (D) and determined the strength of recommendations as strong (1) or weak (2). The potential issues of making strong recommendations based on low-quality evidence were emphasized. Some recommendations were left ungraded (UG). Recommendations were divided into three categories: those directly targeting severe sepsis, those targeting general critical care considered high priority in severe sepsis, and pediatric considerations.

Key recommendations and suggestions, listed by category, include early quantitative resuscitation for sepsis management.

---

### What's hot this year in infectious diseases clinical science [^1165cswW]. Clinical Infectious Diseases (2025). Low credibility.

Clinical science in the field of infectious diseases moved at a rapid pace in 2024. Among the highlights were multiple trials of new antibiotics and new approaches to prevent infections. Concerning trends, with outbreaks of dengue, measles, mpox, and highly pathogenic avian influenza A in 2024, demonstrate the importance of infectious diseases and the continued need for further advances through clinical science. This review highlights some of the most important trials and clinical trends in infectious diseases over the past year.

---

### A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens [^111Mk7De]. Clinical Infectious Diseases (2012). Low credibility.

Multidrug-resistant (MDR) gram-negative pathogens pose a major threat to patients worldwide. Although these organisms remain relatively uncommon overall, their incidence is steadily increasing along with associated increases in mortality and pharmacoeconomic impact. As evidenced by the dearth of new products in the pipeline or in clinical use, the conventional paradigm for the development of drugs against such pathogens is generally ineffectual. We advocate the need for a shift in the paradigm and propose innovative development programs that involve the implementation of a graduated approval process.

- **Initial phase**: The initial phase of the proposed regulatory paradigm includes early approval of a new drug based on a robust nonrandomized study. This is supported by data from controls and a pharmacokinetic-pharmacodynamic package generated from nonclinical studies.

- **Postapproval commitment phase**: The postapproval commitment phase will include a randomized controlled trial, when disease prevalence permits, as well as continued assessment of risks and benefits under "real-world" settings.

---

### Developing outcomes assessments as endpoints for registrational clinical trials of antibacterial drugs: 2015 update from the Biomarkers Consortium of the Foundation for the National Institutes of Health [^117SHfbm]. Clinical Infectious Diseases (2016). Low credibility.

One important component in determining the benefits and harms of medical interventions is the use of well-defined and reliable outcome assessments as endpoints in clinical trials. Improving endpoints can better define patient benefits, allowing more accurate assessment of drug efficacy and more informed benefit-vs-risk decisions; another potential advantage is facilitating efficient trial design. Since our first report in 2012, two Foundation for the National Institutes of Health Biomarkers Consortium Project Teams have continued to develop outcome assessments for potential use as endpoints in registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. In addition, the teams have initiated similar work in the indications of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. This report provides an update on the progress at the time of writing in these four diseases.

---

### Antibacterial drug development: Challenges, recent developments, and future considerations [^112Vq6Hi]. Clinical Pharmacology and Therapeutics (2014). Low credibility.

A decline in antibacterial drug development, coupled with emerging bacterial resistance, has resulted in limited treatment options. One of the challenges facing antibacterial drug development is appropriate clinical trial designs. Noninferiority trials are appropriate for studying new antibacterial drugs for the treatment of serious diseases; however, superiority trials can be challenging and cannot be the only acceptable trial design to study antibacterial drugs. Our efforts must continue to make new therapies available to meet patient needs.

---

### Levofloxacin [^114pbUk5]. U.S. Food and Drug Administration (2019). Low credibility.

Adult patients with clinically and radiologically documented nosocomial pneumonia were enrolled in a multicenter, randomized, open-label study. This study compared intravenous levofloxacin (750 mg once daily), followed by oral levofloxacin (750 mg once daily) for a total of 7–15 days, to intravenous imipenem/cilastatin (500–1000 mg every 6–8 hours daily), followed by oral ciprofloxacin (750 mg every 12 hours daily) for a total of 7–15 days. Levofloxacin-treated patients received an average of 7 days of intravenous therapy (range: 1–16 days); comparator-treated patients received an average of 8 days of intravenous therapy (range: 1–19 days).

Overall, in the clinically and microbiologically evaluable population:

- **Adjunctive therapy**: This was empirically initiated at study entry in 56 of 93 (60.2%) patients in the levofloxacin arm and 53 of 94 (56.4%) patients in the comparator arm. The average duration of adjunctive therapy was 7 days in both arms.

- **Documented Pseudomonas aeruginosa infection**: In clinically and microbiologically evaluable patients, 15 of 17 (88.2%) received ceftazidime (N = 11) or piperacillin/tazobactam (N = 4) in the levofloxacin arm; 16 of 17 (94.1%) received an aminoglycoside in the comparator arm.

- **Suspected methicillin-resistant S. aureus infection**: Vancomycin was added to the treatment regimen of 37 of 93 (39.8%) patients in the levofloxacin arm and 28 of 94 (29.8%) patients in the comparator arm.

---

### Antibiotics: past, present and future [^115FENmy]. Current Opinion in Microbiology (2019). Low credibility.

The first antibiotic, salvarsan, was deployed in 1910. In just over 100 years, antibiotics have drastically changed modern medicine and extended the average human lifespan by 23 years. The discovery of penicillin in 1928 started the golden age of natural product antibiotic discovery, peaking in the mid-1950s. Since then, a gradual decline in antibiotic discovery and development, along with the evolution of drug resistance in many human pathogens, has led to the antimicrobial resistance crisis.

We provide an overview of the history of antibiotic discovery, detailing the major classes of antibiotics and their origins. We argue that the future of antibiotic discovery is promising, as new technologies such as genome mining and editing are being deployed to discover new natural products with diverse bioactivities. Furthermore, we report on the state of antibiotic development, with 45 drugs currently undergoing clinical trials. This includes several new classes with novel modes of action that are in phase 3 clinical trials. Overall, there are promising signs for antibiotic discovery, but changes in financial models are necessary to translate scientific advances into clinically approved antibiotics.

---

### Progress in the fight against multidrug-resistant bacteria 2005–2016: Modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance [^112cwBej]. Clinical Infectious Diseases (2017). Low credibility.

The progressive emergence of bacterial resistance poses a major threat to public health and medical progress. New antibacterial agents, henceforth referred to as antibiotics, with an improved microbiologic spectrum of activity, should be developed before widespread bacterial resistance emerges. This objective creates a paradox: while it is relatively straightforward to demonstrate an agent's improved spectrum in vitro and in preclinical animal infection models, rigorously demonstrating its superior efficacy over existing agents in clinical trials of human infections is challenging.

Inadequately treated acute bacterial infections can be rapidly fatal, necessitating that trial enrollment often proceeds empirically before culture results are available. Therefore, it is crucial that the control arm be predicted to be efficacious in all studies, including those involving potentially superior new agents. If resistance to the control arm is known or suspected, the control arm must be adapted to offer the best available therapy predicted to be efficacious. Ethically, the trial should use an efficacious control and should not expect to demonstrate superiority over an ineffective or substandard control.

The only exception to this ethical imperative arises when there are no efficacious options available for the infecting strain.

---

### Designing an ARDS trial for 2020 and beyond: Focus on enrichment strategies [^113fsQWA]. Intensive Care Medicine (2020). Low credibility.

With the exception of a few successes in trials of supportive care, the majority of interventional clinical trials for acute respiratory distress syndrome (ARDS) have not led to new therapies. To improve the likelihood of benefit from clinical trial interventions in ARDS, clinical trial design must be improved. To optimize trial design, many factors need to be considered, including the type of therapy to be tested, the type of trial (phase 2 or 3), how patients will be selected, primary and secondary endpoints, and strategy for conduct of the trial, including potential newer trial designs such as platform or adaptive trials.

Of these, optimization of patient selection is central to the likelihood of success and is particularly relevant in ARDS, which is a heterogeneous clinical syndrome, not a homogeneous disease. Recent advances, including improved understanding of pathophysiologic mechanisms and better tools for outcome prediction in ARDS, should facilitate both predictive and prognostic enrichment. This commentary focuses on new information and novel methods for prognostic and predictive enrichment that may be useful to optimize patient selection and increase the likelihood of positive clinical trials in ARDS.

---

### Advancing pediatric antibacterial drug development: A critical need to reinvent our approach [^116sBSRL]. Journal of the Pediatric Infectious Diseases Society (2019). Low credibility.

The emergence of antimicrobial resistance to many important bacterial pathogens has renewed interest in developing new antibacterial drugs. The process for advancing these critically needed therapies to the clinic is expected to start with studies that involve adults and will occur well before studies are conducted in children. Although requirements for assessment of the safety and efficacy of new drugs in children as defined in US law are being met, recent experience indicates that the completion of pediatric trials necessary for US Food and Drug Administration (FDA) approval and updated labeling for a pediatric indication for a new antibacterial drug often takes 5 to 10 years after approval for use in adults. Because children are at risk of infection from the same drug-resistant bacteria as adults, it is likely that once a new antibacterial drug is approved for adults, using that drug in children will be considered by many clinicians even before the safety and efficacy of it in children have been established. This use can result in suboptimal treatment of infants and children and underscores an urgent need for the process for developing and evaluating antibacterial drugs for children to be improved and accelerated.

To address this challenge, the Clinical Trials Transformation Initiative, a public–private partnership with funding from the FDA, convened experts to identify factors that contribute to delays in the completion of pediatric antibacterial drug trials and to offer recommendations for improvements. Through extensive discussions and investigations by stakeholders…

---

### A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) [^116oVJGj]. International Journal of Infectious Diseases (2025). High credibility.

The study MK-7655A-016, published in 2025 by Junjie Li and colleagues in the International Journal of Infectious Diseases, focuses on hospital-acquired pneumonia and ventilator-associated pneumonia. The trial seeks to determine if imipenem/cilastatin/relebactam is noninferior to piperacillin/tazobactam in critically ill patients with these conditions.

- **Study design**: The study utilized a multi-center, double-blinded, randomized controlled trial (RCT) framework.

- **Population**: The trial included 270 patients, comprising 72 females and 198 males. Eligible participants were critically ill adults requiring intravenous antibiotics for hospital-acquired or ventilator-associated bacterial pneumonia.

- **Interventions**: Patients were randomly assigned to two groups:
	- n = 134 received imipenem/cilastatin/relebactam (500/250 mg IV) every 6 hours for 7–14 days.
	- n = 136 received piperacillin/tazobactam (4,000/500 mg IV) every 6 hours for 7–14 days.

- **Inclusion criteria**: Critically ill adults with hospital-acquired or ventilator-associated bacterial pneumonia needing intravenous antibiotics.

- **Exclusion criteria**: Key exclusions included the presence of Gram-positive cocci at baseline; pneumonia from community-acquired sources or caused by Mycoplasma, Chlamydia, or Legionella species; pneumonia of viral, fungal, or parasitic origin; carcinoid tumor or syndrome; and active immunosuppression.

- **Primary outcome**: The main measure was the difference in mortality from all causes by day 28, which did not exceed the non-inferiority margin (11.2% vs. 5.9%; absolute difference 5.2%, 95% confidence interval -1.5 to 12.4).

- **Secondary outcomes**: There was no significant difference in favorable clinical response at the end of the treatment period.

---

### Progress in the fight against multidrug-resistant bacteria 2005–2016: Modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance [^1136xvUY]. Clinical Infectious Diseases (2017). High credibility.

Concerns about poorly implemented noninferiority trials have been extensively studied over the past decade. For antibacterial agents, each challenge has been addressed with the high-quality noninferiority designs presented in guidance documents published by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Exhaustive in vitro and animal in vivo exposure–response relationship data for the novel agent are required. Because exposure–response predictions of efficacy in antibacterial drug development are robust, these data provide a high a priori likelihood of efficacy when adequate drug exposures are achieved.

- **Six types of severe bacterial infections**: Recommended for routine study (see Table 1). The characteristics of patients with sufficient severity of illness have been defined, reproducible endpoint measures have been defined, the placebo and active response rates are estimated by exhaustive literature reviews, and a conservative, clinically relevant noninferiority margin has been proposed.

A great advantage of the six infection types recommended by EMA and FDA for the routine study of novel antibacterial agents is that these infections are well-characterized. This choice enables scientifically sound, feasible pathways to accumulate robust data on the efficacy of new agents. Patients with these infections are readily found, can be proven to have severe infection, and are known to have a predictable clinical course in the absence of efficacious antibiotic therapy.

---

### Evidence at time of regulatory approval and cost of new antibiotics in 2016–19: Cohort study of FDA approved drugs [^1122tZeQ]. BMJ Medicine (2022). Low credibility.

The FDA often designates certain clinical trials as pivotal trials when a drug is approved. These trials provide the main body of clinical evidence supporting the drug's efficacy and form the basis for FDA approval. For each pivotal trial, we extracted the indication or indications studied, study population, comparator regimen, primary endpoints, trial size and arms, and statistical hypothesis and analysis plan.

---

### Progress in the fight against multidrug-resistant bacteria 2005–2016: Modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance [^116JZvFP]. Clinical Infectious Diseases (2017). High credibility.

- **Approaches to design of active-control trials for acute infections**: Active-controlled treatment trials compare the efficacy of a new treatment to that of an existing treatment using modern statistical techniques. Such trials can attempt to demonstrate either (1) the statistical superiority of a new agent versus an older agent or (2) the clinically relevant, and statistically defined, degree of comparability of the new therapy to an existing agent.

- **Superiority trials**: Trials designed to demonstrate the superiority of a new agent over an old one are arguably highly desirable. When feasible, they provide extremely convincing evidence of the efficacy advantages of a new agent over an existing therapy. They are unlikely to reach erroneous conclusions due to poor study design and/or conduct, including, for example, use of an endpoint that fails to detect treatment differences or the inclusion of patients who do not have the disease entity of interest (e.g. one does not wish the study population of patients with acute bacterial pneumonia to be diluted by a sizeable subgroup with viral pneumonia). In short, superiority trials are the preferred design for drug development and have been used successfully in many therapeutic areas.

However, challenges arise in the use of superiority designs in the study of acute, severe infections. In contrast to the situation with chronic infections such as tuberculosis, human immunodeficiency virus, or hepatitis C virus infection, where the pace of disease progression permits brief periods of placebo therapy without risk to the patient, acute, severe infections present significant challenges.

---

### Challenges and shortcomings of antibacterial discovery projects [^115Jcvjt]. Clinical Microbiology and Infection (2023). Low credibility.

Analyses of preclinical funding applications highlight the growing number of applications focusing on narrow-spectrum, non-traditional agents and projects against non-critical priority pathogens as defined by the WHO. An important reason for the low number of discovery projects against the gram-negative critical priority pathogens, despite the strong medical need, is the scientific challenge of the permeability barrier of two-membrane cell envelopes and broad efflux systems in gram-negative bacteria. Incomplete knowledge of how to break this barrier is still a major obstacle, despite recent progress in understanding correlations between the physicochemical properties of compounds and their permeation across the two-membrane cell envelopes in the presence of efflux. The complexity of defining the rules for bacterial intracellular accumulation across species and scaffolds often results in narrow-spectrum or even single-pathogen agents.

Antibacterial drug discovery involves trying to balance many different and sometimes seemingly opposing pressures on design strategy. If this cannot be achieved with reasonable resources, the focus is often shifted to single-pathogen or non-systemic approaches, such as therapies against Clostridioides difficile or inhaled applications. Thus, fundamental scientific challenges shape many drug discovery programmes.

---

### Recognizing and managing sepsis: What needs to be done [^114F6J9r]. BMC Medicine (2015). Low credibility.

Attention to the pre-hospital phase in patients with sepsis is clearly critical. The initial link in this chain is to increase awareness of the symptoms of sepsis amongst the general public. Organizations such as the Global Sepsis Alliance and initiatives like World Sepsis Day, which work to raise awareness of sepsis, play a crucial role in alerting the general public about the importance of seeking medical attention when they or a loved one displays the symptoms of sepsis.

Pre-hospital care also plays an important role in recognizing and providing prompt care for patients with sepsis. Approximately 50% of the patients who present to the emergency department with sepsis will arrive via an Emergency Medical Service (EMS). This exposure provides an excellent opportunity to improve early recognition of sepsis and to commence an integrated system of care for these complex patients. For example, in a pilot prospective cohort study conducted in the pre-hospital setting, early identification of patients with severe sepsis by EMS providers utilizing a screening tool and a point-of-care venous lactate meter was shown to be feasible. Once identified, there is scope for interventions, such as intravenous cannulation and initiation of intravenous fluids provided pre-hospital, to influence the outcomes of patients with sepsis.

An enhanced focus on the identification of sepsis in the emergency department setting, as recommended by the Surviving Sepsis Campaign Guidelines, has been shown in numerous studies to be associated with improved outcomes. Identifying patients with sepsis in a bu

---

### Tigecycline [^1143NTxK]. U.S. Food and Drug Administration (2020). High credibility.

- **Mortality imbalance and lower cure rates in hospital-acquired pneumonia**: A trial of patients with hospital-acquired, including ventilator-associated, pneumonia failed to demonstrate the efficacy of tigecycline. In this trial, patients were randomized to receive tigecycline (100 mg initially, then 50 mg every 12 hours) or a comparator. In addition, patients were allowed to receive specified adjunctive therapies. The subgroup of patients with ventilator-associated pneumonia who received tigecycline had lower cure rates (47.9% versus 70.1% for the clinically evaluable population).

	Greater mortality was observed in patients with ventilator-associated pneumonia who received tigecycline (25/131 [19.1%] versus 15/122 [12.3%] in comparator-treated patients) [see Adverse Reactions (6.1)]. Particularly high mortality was seen among tigecycline-treated patients with ventilator-associated pneumonia and bacteremia at baseline (9/18 [50.0%] versus 1/13 [7.7%] in comparator-treated patients).

- **Anaphylactic reactions**: Anaphylactic reactions have been reported with nearly all antibacterial agents, including tigecycline, and may be life-threatening. Tigecycline is structurally similar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs.

- **Hepatic adverse effects**: Increases in total bilirubin concentration, prothrombin time, and transaminases have been observed in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported.